
Telus Ventures is set to exit healthcare data management software producer Get Real Health in an $11m purchase by CPSI, six years after it invested.
Grove Collaborative has agreed to purchase the video commerce platform in a deal of undisclosed size that will allow CAA Ventures to exit.
Digital media company Cheddar has agreed to a purchase by investor Altice USA that will also provide exits for Antenna Group, Dentsu, Liberty Global, Comcast, Amazon, AT&T, NYSE and Broadway Video.
Alphabet, WuXi AppTec, Celgene, Roche and Novartis are in line to exit precision oncology therapy developer Ideaya Biosciences, which has filed to go public.
The We Company, valued at $47bn as of January, confidentially filed for an IPO in December that would provide exits for SoftBank and Jin Jiang International.
Axiata Digital will divest a 30 company-strong corporate venturing portfolio valued at $140m to Pegasus 7 Ventures, an investment firm run by one of its ex-executives.
Astellas, Novartis and GlaxoSmithKline are in line for exits as oncology drug developer Bicycle Therapeutics prepares to float, having filed to raise $86m in its IPO.
The drug developer has confidentially filed for an IPO having collected $124m in funding from investors including PureTech Health, Nan Fung and Alexandria Real Estate Equities.
Media group Nikkei has bought a controlling interest in corporate-backed financial news publication DealStreetAsia, allowing Singapore Press Holdings to sell shares.
SoftBank Vision Fund owns more than 7% of the enterprise messaging platform developer, which could list at a valuation near $17bn.